Hamza ÖZAVCI, Mustafa KAPLAN

4422

Cloning and molecular characterization of thiol-specific antioxidant gene of Leishmania tropica Turkey isolate

Cloning and molecular characterization of thiol-specific antioxidant gene of Leishmania tropica Turkey isolate

Background/aim: Thiol-specific antioxidant (TSA) protein is one of the most promising molecules among candidates for vaccineagainst cutaneous leishmaniasis. It was found to be significantly protective against different Leishmania species. In this study, cloningand molecular characterization of thiol-specific antioxidant gene of L. tropica Turkey isolate (LtTSA) were aimed.Materials and methods: LtTSA was amplified by PCR using the specific primers of TSA gene and cloned into the pcDNA3.1 vector.The cloning was confirmed by PCR screening, restriction enzyme reactions, and DNA sequence analysis. Finally, three-dimensionalstructure and antigenic properties of the protein encoded by the LtTSA were determined.Results: Six hundred base pair bands belonging to LtTSA were shown with electrophoresis. It was found that LtTSA and its encodedprotein have high similarity with different Leishmania species. LtTSA protein consisting of 199 amino acids was found to have 7 differentantigenic regions.Conclusion: LtTSA and its encoded TSA protein were found to be highly immunogenic and similar to TSA proteins previously testedas a vaccine candidate.
PDF

___

  • 1. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191-1199.
  • 2. Yazar S, Kuk S, Miman Ö, Saygı G. Saygı’nın Temel Tıbbi Parazitolojisi. Kayseri, Turkey: Erciyes Üniversitesi Yayınları; 2016 (in Turkish).
  • 3. World Health Organisation. Investing to overcome the global impact of neglected tropical diseases: third world health organisation report on neglected diseases. 2015.
  • 4. Harris M, Reza J. Global report for research on infectious disease of poverty. World Health Organization. 2012.
  • 5. Choi CM, Lerner EA. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc 2001; 6: 175-182.
  • 6. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol and Infect Dis 2004; 27: 305-318.
  • 7. Showler AJ, Boggild AK. Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015. Curr Infect Dis Rep 2015; 17: 489.
  • 8. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its insidance. PloS One 2012; 7: e35671.
  • 9. World Health Organisation. Control of the Leishmaniases. Geneva, Switzerland: WHO Technical Report Series; 2010.
  • 10. Ghosh M, Bandyopadhyay S. Present status of antileishmanial vaccines. Mol Cell Biochem 2003; 253: 199-205.
  • 11. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 2011; 11: 1464-1488.
  • 12. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, Modabber F, Campos-Neto A, Reed SG. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002; 70: 4215-4225.
  • 13. Fatemeh G, Fatemeh T, Zohreh S, Abdolhosein D, Mohammad Zahir H, Mehdi M. Cloning of a recombinant plasmid encoding thiol-specific antioxidant antigen (TSA) gene of Leishmania major and expression in the Chinese hamster ovary cell line. Malays J Med Sci 2012; 19: 15-19.
  • 14. Ghaffarifar F, Jorjani O, Sharifi Z, Dalimi A, Hassan ZM, Tabatabaie F, Khoshzaban F, Hezarjaribet HZ. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS 2013; 121: 290-298.
  • 15. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine 2016; 34: 2992-2995.
  • 16. Jirata D, Kuru T, Genetu A, Barr S, Hailu A, Aseffa A, Gedamu L. Identification, sequencing and expression of peroxidoxin genes from Leishmania aethiopica. Acta Trop 2006; 99: 88-96.
  • 17. Maspi N, Ghaffarifar F, Sharifi Z, Dalimi A. Co-delivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice. Parasite Immunol 2016; 38: 228-235.
  • 18. Monnerat S, Martinez-Calvillo S, Worthey E, Myler PJ, Stuart KD, Fasel N. Genomic organization and gene expression in a chromosomal region of Leishmania major. Mol Biochem Parasit 2004; 134: 233-243.
  • 19. Sakai S, Takashima Y, Matsumoto Y, Reed SG, Hayashi Y, Matsumoto Y. Intranasal immunization with leish-111f induces IFN-gamma production and protects mice from Leishmania major infection. Vaccine 2010; 28: 2207-2213.
  • 20. Salay G, Dorta ML, Santos NM, Mortara RA, Brodskyn C, Oliveira CI, Barbieri CI, Rodrigues MM. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the new world. Clin Vaccine Immunol 2007; 14: 1173-1181.
  • 21. Tabatabaie F, Mahdavi M, Faezi S, Dalimi A, Sharifi Z, Akhlaghi L, Ghaffarifar F. Th1 platform immune responses against Leishmania major induced by thiol-specific antioxidant-based DNA vaccines. Jundishapur J Microbiol 2014; 7: e8974.
  • 22. Mendez S, Belkaid Y, Seder RA, Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002; 20: 3702-3708.
  • 23. Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, Reed SG. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66: 3279-3289.
  • 24. Modabber F. Leishmaniasis vaccines: past, present and future. J Antimicrob Agents 2010; 36: S58-S61.
  • 25. Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of Leishmania vaccines: predicting the future from past and present experience. J Biomed Res 2013; 27: 85-102.
  • 26. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008; 26: 1709-1724.
  • 27. Seyed N, Taheri T, Rafati S. Post-genomics and vaccine improvement for Leishmania. Front Microbiol 2016; 7: 467.
  • 28. Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasites Vectors 2016; 9: 277.
  • 29. Meriee M, Soukkarieh C, Abbady AQ. Molecular cloning and expression of the Leishmania tropica KMP-11 gene. J Egypt Soc Parasitol 2014; 44: 321-328.
  • 30. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276: 172-174.
  • 31. Harman M. Cutaneous leishmaniasis. Turk J Dermatol 2015; 9: 168-176. (article in Turkish with an abstract in English).
  • 32. Inci R, Ozturk P, Mulayim MK, Ozyurt K, Alatas ET, Inci MF. Effect of the Syrian civil war on prevalence of cutaneous leishmaniasis in southeastern Anatolia, Turkey. Med Sci Monit 2015; 21: 2100-2104.
  • 33. Koltas IS, Eroglu F, Alabaz D, Uzun S. The emergence of Leishmania major and Leishmania donovani in southern Turkey. Trans R Socf Trop Med Hyg 2014; 108: 154-158.
  • 34. Ok Ü, Balcığlu İ, Özkan AT, Özensoy S, Özbel Y. Leshmaniasis in Turkey. Acta Trop 2002; 84: 43-48.
  • 35. Zeyrek FY, Korkmaz M, Özbel Y. Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa province, Turkey, where ACL is higly endemic. Clin Vaccine Immunol 2007; 14: 1409-1415.
  • 36. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4(+) T cells. Infection Immun 2007; 75: 4648-4654.
  • 37. Ghalib H, Modabber F. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol Dis 2007; 6: 7.
  • 38. Ramirez JR, Gilchrist K, Robledo S, Sepulveda JC, Moll H, Soldati D, Berberich C. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP11 elicit a specific immune response in BALB/c mice. Vaccine 2001; 20: 455-461.
  • 39. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20: 3292-3303.
  • 40. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, Goto Y, Guderian J, Howard RF, Reed SG. Treatment of canine visceral leishmaniasis by the vaccine leish111f+MPL-SE. Vaccine 2010; 28: 3333-3340.
  • 41. Turgay N. Last updates on leishmania vaccine studies: when are we going to be vaccinated? Turkiye Parazitol Derg 2005; 29: 232-234 (article in Turkish with an abstract in English).
  • 42. Daifalla NS, Bayih AG, Gedamu L. Differential immune response against recombinant Leishmania donovani peroxidoxin 1 and peroxidoxin 2 proteins in BALB/c mice. J Immunol Res 2015; 2015: 348401.
  • 43. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 2006; 123: 423-438.
  • 44. Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012; 30: 3834-3842.
  • 45. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/ LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 2002; 70: 2828-2836.
  • 46. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Khan SJ, Beckmann AM et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009; 28: 329- 337.
  • 47. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. Transl Res 2013; 162: 144-155.
  • 48. Kuk S, Erensoy A. Gene cloning, selection of plasmids and application of Fasciola hepatica cathepsin L1 gene. Turkiye Parazitol Derg 2008; 32: 16-22. (article in Turkish with an abstract in English).
  • 49. Sambrook J Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York, NY, USA: Cold Spring Harbor Laboratory Press; 1989.
  • 50. İça A. Canine Leishmaniosis. J Fac Vet Med Univ Erciyes 2004; 1: 119-124 (article in Turkish with an abstract in English).
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Qiang GU, Jin Chao HOU, Xiang Ming FANG

Sümeyye EKMEKCİ, Ülkü KÜÇÜK, Yelda DERE, İzzetiye Ebru ÇAKIR, Hatice Ceren SAYAR, Batuhan ERGANİ, Özgür ÇAKMAK, Ozan BOZKURT, Kutsal YÖRÜKOĞLU

Bariş SEVİNÇ, Nurullah DAMBURACI, Murat GÜNER, Ömer KARAHAN

İlknur Külhaş ÇELİK, Ersoy CİVELEK, Ayşe METİN, Tayfur GİNİŞ, Müge TOYRAN, Emine Dibek MISIRLIOĞLU, Can Naci KOCABAŞ

Rabia Lebriz Uslu BEŞLİ, Muhammet Sait SAĞER, Elife AKGÜN, Sertaç ASA, Onur Erdem ŞAHİN, Çetin DEMİRDAĞ, Ekrem GÜNER, Seyedbaresh RAZAVİKHOSROSHAHİ, Emre KARAYEL, Hüseyin PEHLİVANOĞLU, Aslan AYGÜN, İlhami USLU, Zübeyr TALAT, Kerim SÖNMEZOĞLU

In silico design and in vitro development of a highly accurate test to detect Brucella species

Somayeh TAVAKOLI, Setareh SHAHNAZARI, Hosein SAFARI, Maysam MARD-SOLTANI, Bahman KHALESI

Lamia MAKNI, Cherif Ben HAMDA, Abrar Al ANSARI, Oussema SOUAIAI, Ezzedine GAZOUANI, Amel MEZLINI, Wassim Y ALMAWI, Besma YACOUBI-LOUESLATI

İlkben GÜNÜŞEN, Asuman SARGIN, Ali AKDEMİR, Ahmet Mete ERGENOĞLU

Gül Sema Yildiran KESKİN, Özant HELVACI, Çağri YAYLA, Özge Tuğçe PAŞAOĞLU, Çağlar KESKİN, Selim Turgay ARINSOY, Ülver DERİCİ

Lütfi SOYLU, Oğuz Uğur AYDIN, Mehmet YILDIZ, Hacer SERDAROĞLU, Murat KURTOĞLU, Sedat KARADEMİR